… How do we interpret the vast amount of data culled from genome-wide sequencing, and translate these early … long been overwhelmed with the vast amount of data gathered from genome-wide sequencing,” says Singleton. “But we are … without a cure for HD. Another recent dose of reality comes from a new study from Johns Hopkins University that suggests …

… strategy of de-risking early research for larger investment from venture capitalists and industry partners, two projects … to encourage vital partnerships down the road. Investments from venture capital firms and large companies can help … (GCase) in the brain. Loss of GCase enzyme activity, from mutations in the GBA1 gene, has been linked to …

… middling or negative results .  While negative results from several clinical trials certainly doesn’t mean the end … those large-scale upcoming clinical studies; it’s still far from being a sure thing.  Science still has some work to do … linked to a higher risk of developing PD, scientists from The Michael J. Fox Foundation’s (MJFF) Parkinson’s …

… Yesterday Denali Therapeutics announced positive results from its first-in-human LRRK2 inhibitor clinical trial. The … Read more below on this project and its treatment potential from our earlier report on Denali's initial public offering. … to measure inhibition, including one based on a finding from a Michael J. Fox Foundation-organized consortium …

… is to develop the methods to assess LRRK2 activity directly from tissue in pre-clinical models relevant to Parkinson’s … formation of active LRRK2 conformations in tissue derived from pre-clinical models treated with compounds that inhibit …

… This grant builds upon the research from a prior grant: Functional Analysis of LRRK2 Promising … Investigation:  Some of the findings which we generated from our original proposal as well as new and emerging …